Older age of onset of sjogren's has more sicca than younger and older slightly less antibodies in a large group of Sjogrens pts from many countries. Also older mean age of onset than previous yrs like RA found #EULAR2019 @RheumNow abs THU0277 https://t.co/bRMVtyYCkJ

Reade Amsterdam Gout study of 75 gout (many polyarticular) found neutrophil extracellular traps or NETS are increased in #gout patients and NETS correlate with cardiovascular risk. #Eular2019 OP0300 https://t.co/ZVeL9ltF7B

7/72 pts treated with PD-1 inh monotherapy developed de novo inflamm arthritis irAEs confirmed on USS (three PD, four greyscale synovitis). More and more centers reporting >5% inflamm arthritis irAEs - its presence is underestimated! #EULAR2019 THU0035 Sapienza, Rome @RheumNow https://t.co/zWpUtEAEMa

2. Riociguat has beneficial impact on Raynaud’s phenomenon and digital ulcers in RISE-SSC. #EULAR2019. Poster tour today FR0303 @RheumNow @BayerPharma @UMIntMed

Dr. van der Heijde presents results of dual neutralization of Il-17A and F with bimekizumab which may provide a new therapeutic option for patients with AxSpA. Abstract OPO231. #EULAR2019 @RheumNow #spondylitis https://t.co/caOkc47jyn

Dr. Xenofon Baraliakos presents the MAXIMISE trial which showed improvement in axial involvement in PsA patients treated with secukinumab. Abstract OPO235 #EULAR2019 @RheumNow #spondylitis #Novartis https://t.co/exxbgIxgJT

Ciurea, Switzerland: no clear benefit of switching to IL-17i rather than another TNFi after failed TNFi in #axial #spondyloarthritis... might even be trend to reduced outcomes in men. Nice example of real-world data challenging largely “evidence-free” dogma #EULAR2019 @RheumNow

No increase in immunogenicity after switching (1 or more) from originator IFX to biosimilars in pts with #RheumatoidArthritis according to a prospective study by Lauret et al. #EULAR2019 @RheumNow #Rheumatology https://t.co/SB89O1Kdc2

GCA patients have decreased proportions of PD1+CD4+ Th cells compared to normal controls, building on previous Weyand lab work. Once again, irAEs and PMR/GCA might be friends? #EULAR2019 FRI0266 Hid Cadena from Elisabeth Brouwer’s group @RheumNow https://t.co/H6bhO1jH2S

Mayo RCT on Flares in established RA randomized 150 pts to usual care or a flare (pt self declared) survey scheme found pts flaring prefer self management 62% over expedited clinic visit 32%, but intervention was no better than usual care! OP0309 #Eular2019 https://t.co/zGlW43ppqi

Beautifully presented abstract on protective effect of LLDAS independent of baseline disease activity&damage status. Protection is higher in pts with active disease (SLEDAI >=6) and those already had damage accrual (SDI>=1). #eular2019 #aplc @EricFMorand @Monash_FMNHS @RheumNow

Performance of ACR CRISS in different recent trials. Superior to mRSS.#EULAR2019. @RheumNow https://t.co/giQEiFd0Uv

Central and peripheral site readers of SI joint MRIs - how do they fare in the nr-axSpA era? #EULAR2019 THU0359 from ASAS @RheumNow https://t.co/9RI22Gb7jx

Clinical practice-friendly VAS assessIng different aspects of Rheum diseases: physicians rated #gout inflammation, damage, and global scores as high/higher than RA. Dr Nika discusses. Let’s have high levels of gout treat-to-target strategy discussions too! @RheumNow #EULAR2019 https://t.co/wMf7yR2GPA

Does age of onset of Sjögren's syndrome change % with sicca symptoms (dry eyes & mouth)? #EULAR2019 @RheumNow